Literature DB >> 16331286

RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.

Keith R Bley1, Anindya Bhattacharya, Don V Daniels, Joel Gever, Alam Jahangir, Counde O'Yang, Steven Smith, Dinesh Srinivasan, Anthony P D W Ford, Mary-Frances Jett.   

Abstract

Prostacyclin (PGI2) possesses various physiological functions, including modulation of nociception, inflammation and cardiovascular activity. Elucidation of these functions has been hampered by the absence of selective IP receptor antagonists. Two structurally distinct series of IP receptor antagonists have been developed: 4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) and R-3-(4-fluoro-phenyl)-2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-propionic acid (RO3244794).RO1138452 and RO3244794 display high affinity for IP receptors. In human platelets, the receptor affinities (pKi) were 9.3 +/- 0.1 and 7.7 +/- 0.03, respectively; in a recombinant IP receptor system, pKi values were 8.7 +/- 0.06 and 6.9 +/- 0.1, respectively. Functional antagonism of RO1138452 and RO3244794 was studied by measuring inhibition of carbaprostacyclin-induced cAMP accumulation in CHO-K1 cells stably expressing the human IP receptor. The antagonist affinities (pKi) of RO1138452 and RO3244794 were 9.0 +/- 0.06 and 8.5 +/- 0.11, respectively. Selectivity profiles for RO1138452 and RO3244794 were determined via a panel of receptor binding and enzyme assays. RO1138452 displayed affinity at I2 (8.3) and PAF (7.9) receptors, while RO3244794 was highly selective for the IP receptor: pKi values for EP1 (< 5), EP3 (5.38), EP4 (5.74) and TP (5.09). RO1138452 (1-10 mg kg(-1), i.v.) and RO3244794 (1-30 mg kg(-1), i.v.) significantly reduced acetic acid-induced abdominal constrictions. RO1138452 (3-100 mg kg(-1), p.o.) and RO3244794 (0.3-30 mg kg(-1), p.o.) significantly reduced carrageenan-induced mechanical hyperalgesia and edema formation. RO3244794 (1 and 10 mg kg(-1), p.o.) also significantly reduced chronic joint discomfort induced by monoiodoacetate. These data suggest that RO1138452 and RO3244794 are potent and selective antagonists for both human and rat IP receptors and that they possess analgesic and anti-inflammatory potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331286      PMCID: PMC1751302          DOI: 10.1038/sj.bjp.0706554

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

Review 1.  Prostanoid receptor heterogeneity through alternative mRNA splicing.

Authors:  K L Pierce; J W Regan
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

Review 2.  Molecular biology of prostanoid receptors; an overview.

Authors:  F Ushikubi; M Hirata; S Narumiya
Journal:  J Lipid Mediat Cell Signal       Date:  1995-10

3.  A novel subtype of prostacyclin receptor in the central nervous system.

Authors:  Y Watanabe; K Matsumura; H Takechi; K Kato; H Morii; M Björkman; B Långström; R Noyori; M Suzuki; Y Watanabe
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

4.  COX-2-derived prostacyclin confers atheroprotection on female mice.

Authors:  Karine M Egan; John A Lawson; Susanne Fries; Beverley Koller; Daniel J Rader; Emer M Smyth; Garret A Fitzgerald
Journal:  Science       Date:  2004-11-18       Impact factor: 47.728

5.  Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.

Authors:  M F Jett; C S Ramesha; C D Brown; S Chiu; C Emmett; T Voronin; T Sun; C O'Yang; J C Hunter; R M Eglen; R M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

6.  Functional role of prostacyclin receptor in rat dorsal root ganglion neurons.

Authors:  Koichi Nakae; Fumihiko Hayashi; Mayumi Hayashi; Noriyuki Yamamoto; Takashi Iino; Satoru Yoshikawa; Jang Gupta
Journal:  Neurosci Lett       Date:  2005-11-18       Impact factor: 3.046

7.  A novel subtype of the prostacyclin receptor expressed in the central nervous system.

Authors:  H Takechi; K Matsumura; Y Watanabe; K Kato; R Noyori; M Suzuki; Y Watanabe
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

8.  Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation.

Authors:  Stephen J Wilson; Aoife M Roche; Ekaterina Kostetskaia; Emer M Smyth
Journal:  J Biol Chem       Date:  2004-10-07       Impact factor: 5.157

Review 9.  The role of IP prostanoid receptors in inflammatory pain.

Authors:  K R Bley; J C Hunter; R M Eglen; J A Smith
Journal:  Trends Pharmacol Sci       Date:  1998-04       Impact factor: 14.819

10.  Characterization of prostanoid receptor-evoked responses in rat sensory neurones.

Authors:  J A Smith; S M Amagasu; R M Eglen; J C Hunter; K R Bley
Journal:  Br J Pharmacol       Date:  1998-06       Impact factor: 8.739

View more
  31 in total

1.  Inhibitory effect of schisandrin on spontaneous contraction of isolated rat colon.

Authors:  Jiaming Yang; Paul S P Ip; John H K Yeung; Chun-Tao Che
Journal:  Phytomedicine       Date:  2011-04-21       Impact factor: 5.340

2.  Endothelin-1 attenuates increases in hydraulic conductivity due to platelet-activating factor via prostacyclin release.

Authors:  Elizabeth L Cureton; Aaron Strumwasser; Rita O Kwan; Kristopher C Dozier; Brian Curran; Javid Sadjadi; Gregory P Victorino
Journal:  J Appl Physiol (1985)       Date:  2010-12-23

3.  Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.

Authors:  Emilia Falcetti; Susan M Hall; Peter G Phillips; Jigisha Patel; Nicholas W Morrell; Sheila G Haworth; Lucie H Clapp
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist.

Authors:  Wesam Bassiouni; Tahia Daabees; Xavier Norel; Amira M Senbel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-14       Impact factor: 3.000

6.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

7.  ONO-54918-07, a stable prostacyclin analogue, mimics the effect of prostaglandin PGE1 on NG108-15 cells.

Authors:  Adolfo Cavalié; Stephan Ernst Philipp; Hans Meves
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

8.  Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop.

Authors:  Karl Deacon; Alan J Knox
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 9.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

10.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.